Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zarbá, J. J.
Right arrow Articles by Arroyo, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zarbá, J. J.
Right arrow Articles by Arroyo, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1285-1290, 2003
© 2003 European Society for Medical Oncology

Original Paper

A phase I–II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma

J. J. Zarbá+, A. V. Jaremtchuk, P. Gonzalez Jazey, M. Keropian, R. Castagnino, C. Mina and G. Arroyo

GETICS, Yerba Buena, Tucumán, Argentina

Received 6 January 2003; revised 12 March 2003; accepted 28 April 2003

Background:

The purpose of this study was to determine the maximum-tolerated dose (MTD) and the antitumor activity of gemcitabine when administered in combination with concurrent cisplatin and radiotherapy in locally advanced cervical carcinoma (LACC).

Patients and methods:

Patients with histologically confirmed LACC (International Federation of Gynecology and Obstetrics IIB–IVA), previously untreated, were eligible for entry in the study to receive radiotherapy and concomitant weekly chemotherapy with cisplatin 40 mg/m2 and gemcitabine at increasing doses levels until the MTD was found.

Results:

Thirty-six patients were included. Sixteen patients were entered at four dose levels. The MTD was 150 mg/m2 and the recommended dose of gemcitabine for phase II was 125 mg/m2. Twenty additional patients were entered at this level. Toxicity at the recommended dose was acceptable with grade 3/4 toxicity in <20% of patients. Thirty-five of thirty-six patients (97.3%) achieved an objective response, 32 (88.8%) a complete response (CR) three a (8.3%) partial response and one (2.7%) stable disease. At a median follow-up of 26 months, 28 of 36 patients (77.7%) are in sustained complete remission and seven of 36 (19.4%) have relapsed. The 3-year disease-free and overall survival rates are 67% and 72%, respectively.

Conclusion:

The association of cisplatin and gemcitabine with concurrent radiotherapy is active and well-tolerated in untreated LACC.

Key words: cervical cancer, cisplatin, concurrent chemoradiotherapy, gemcitabine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
B. Pauwels, A. E.C. Korst, F. Lardon, and J. B. Vermorken
Combined Modality Therapy of Gemcitabine and Radiation
Oncologist, January 1, 2005; 10(1): 34 - 51.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.